Lancet
Obesity Week 2025: Once-weekly amylin receptor agonist results in up to 20% weight loss
The weight loss potential of eloralintide, a selective amylin receptor agonist, approaches that of leading incretin-based therapies, with a favorable safety profile and once-weekly dosing. The results were presented at Obesity Week 2025.
Study details: This multicenter, double-blind, randomized, placebo-controlled phase 2 trial (NCT06230523) enrolled 263 adults (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity, no diabetes) across 46 U.S. sites. Participants received weekly SC eloralintide (1–9 mg, fixed or escalated dosing) or placebo for 48 weeks. Primary endpoint was percent change in bodyweight from baseline.
Results: Eloralintide produced clinically meaningful, dose-dependent weight loss: mean percent change ranged from -9% (1 mg) to -20% (9 mg, 6–9 mg escalation) vs. -0.4% for placebo. The most frequent adverse events were nausea (up to 64% at 6 mg) and fatigue (up to 46% at 6–9 mg), generally mild to moderate and dose-related.
Source:
Billings LK, et al. (2025, November 6). Lancet. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/41207310/